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Abstract: Targeting antigen to dendritic cells (DCs) is a powerful and novel strategy for 
vaccination. Priming or loading DCs with antigen controls whether subsequent immunity will 
develop and hence whether effective vaccination can be achieved. The goal of our present work 
was to increase the potency of DC-based antitumor vaccines by overcoming inherent limitations 
associated with antigen stability and cross-presentation. Nanoparticles prepared from the biode-
gradable polymer poly(lactic-co-glycolic acid) have been extensively used in clinical settings for 
drug delivery and are currently the subject of intensive investigation as antigen delivery vehicles 
for vaccine applications. Here we describe a nanoparticulate delivery system with the ability to 
simultaneously carry a high density of protein-based antigen while displaying a DC targeting 
ligand on its surface. Utilizing a targeting motif specific for the DC-associated surface ligand 
DEC-205, we show that targeted nanoparticles encapsulating a MART-127–35 peptide are both 
internalized and cross-presented with significantly higher efficiency than isotype control-coated 
nanoparticles in human cells. In addition, the DEC-205-labeled nanoparticles rapidly escape 
from the DC endosomal compartment and do not colocalize with markers of early (EEA-1) 
or late endosome/lysosome (LAMP-1). This indicates that encapsulated antigens delivered by 
nanoparticles may have direct access to the class I cytoplasmic major histocompatibility com-
plex loading machinery, overcoming the need for “classical” cross-presentation and facilitating 
heightened DC stimulation of anti-tumor CD8+ T-cells. These results indicate that this delivery 
system provides a flexible and versatile methodology to deliver melanoma-associated antigen 
to DCs, with both high efficiency and heightened potency.
Keywords: dendritic cells, DEC-205, PLGA nanoparticles, cross-presentation, melanoma-
associated antigen 
Introduction
Dendritic cell (DC)-based immunotherapy for the treatment of solid tumors is premised 
on the possibility that tumor-associated antigens, or distinctive proteins on the tumor 
cell surface, can generate a clinically relevant immune response. DCs are professional 
antigen-presenting cells (APC) that have the capacity to process internalized antigens 
(Ag) for cross-presentation to anti-tumor CD8+ cytotoxic T-lymphocytes (CTLs) in the 
context of class I major histocompatibility complexes (MHC I), and are therefore able 
to initiate host T-cell responses against foreign Ag and tumors.1 As a consequence, 
promising strategies for priming T-cell immunity focus on manipulating the DC 
response by targeting Ag delivery through specific DC surface receptors, including 
C-type lectin receptors (CLRs).
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CLRs are present on the surface of DCs and recognize 
sugar moieties, including mannose, fucose, and glucan 
expressed on the surface of mycobacteria, fungi, and viruses.2 
The ability of CLRs to internalize Ag and deliver them to 
endocytic compartments for processing and Ag presentation 
has been one of the main reasons that CLRs are targeted for 
the induction of tumor-specific immune responses.3 Steinman 
et al have pioneered the field of antibody-mediated targeting 
of Ag to DCs through several CLRs, including DEC-205,4 
Langerin,5 and DC-SIGN.6 In particular, the role of DEC-205 
in targeting tumor antigens to DCs has recently garnered 
significant interest in the field of tumor immunology because 
DEC-205 is expressed at relatively high levels on myeloid 
blood DCs.7 In recent in vitro studies, antibody-mediated 
delivery of HIV gag p24 protein to DEC-205 on human 
monocyte-derived DCs resulted in the presentation of differ-
ent MHC class I-restricted peptides,8 and DEC-205-mediated 
targeting of plasmacytoid DCs by nanoparticles (NPs) led to 
increased cross-presentation of a melanoma-associated Ag.9 
Thus, DEC-205 targeting of Ag to DCs is a promising poten-
tial methodology to improve cell-based antitumor vaccines.
Melanoma is an excellent candidate for DC-based 
immunotherapy, as it is well recognized to be immunogenic. 
Recently, a number of human melanoma-associated antigens 
recognized by T lymphocytes have been identified. Among 
them, the MART-1 (melanoma antigen recognized by T-cells) 
gene is expressed by normal melanocytes, as well as by a 
majority of fresh tumor isolates and melanoma cell lines. 
The MART-127–35
 peptide (corresponding to residues 27–35 
of the non-mutated MART-1 protein) is a well characterized 
immune-dominant epitope for human leukocyte antigen 
(HLA)-A2-restricted melanoma-specific CTLs and can be 
used for the development of immunotherapeutic strategies.10 
Thus far, however, therapeutic benefits associated with DC/
peptide vaccination alone in patients with melanoma have 
been limited.11 And while there has been a great deal of recent 
excitement regarding new classes of chemotherapeutic agents, 
such as selective BRAF inhibitors in treatment of advanced 
melanoma, concerns regarding formation of secondary malig-
nancies and rapid development of drug-resistant tumors make 
a clear case for combining chemotherapy agents with agents 
that stimulate the immune system.12 Perhaps the strongest 
cases for immunomodulation in the treatment of advanced 
melanoma were the tumor regressions observed in up to 
50% of metastatic melanoma patients receiving expanded 
autologous melanoma-specific T lymphocytes and high-
dose interleukin (IL)-2, as well as the recent effectiveness of 
monoclonal antibody therapies blocking the T-cell negative 
regulators CTLA-4 and PD-1.13 These results point to the 
critical role of stimulating functional antitumor T-cells in 
attaining durable responses in advanced disease, and if meth-
odologies to increase the potency of DC-based vaccination 
strategies could be developed, they would be excellent candi-
dates for synergistic use with these promising new agents. 
Two of the most important factors limiting conventional 
DC vaccination are the rapid degradation of internalized 
protein by DC if whole protein Ag is utilized, as well as the 
transient nature of MHC class I epitopes at the DC surface 
following external loading of motif-fitting peptides.14 Encap-
sulation of Ag in polymeric NPs has been demonstrated in 
the literature to protect Ag from degradation by lysosomal 
proteases, potentially by facilitating endosomal escape 
of encapsulated Ags,15 as well as increasing and prolong-
ing Ag release, leading to more efficient presentation of 
MHC-peptide complexes to CD8+ T-cells.16,17 Moreover, the 
particulate nature of these systems permits their rapid inter-
nalization by DCs, perhaps due to their pathogen-mimicking 
size and charge profile, an effect that can be heightened 
by surface decoration of NPs with defined PAMP.18 How-
ever, comparatively little is known about whether immune 
responses induced by NPs can be further enhanced by direct-
ing Ag-containing NPs via cell surface lectin receptors such 
as DEC-205 to human monocyte-derived DCs, the principal 
cell type utilized clinically in antitumor vaccination. It is 
understood that the presence and density of anti-DEC-205 on 
NPs in the mouse system can enhance a vaccine response,19 
but outside of recent targeting of plasmacytoid DCs as APC,9 
very little is known regarding the efficiency of this targeted 
approach and its mechanistic impact on cross-presentation in 
human DC populations. To test this, we designed experiments 
to determine whether targeting the DEC-205 receptor on 
human DCs via NPs could enhance DC Ag cross-presentation 
to melanoma patient-derived CD8+ antitumor T-cells. We 
engineered a NP-based delivery system utilizing the poly-
mer poly(lactic-co-glycolic acid) (PLGA), which is already 
approved by the US Food and Drug Administration and has 
generated intense interest because of its favorable proper-
ties, which include excellent biocompatibility, biodegrad-
ability, and mechanical strength.20–22 PLGA-based delivery 
systems for a variety of pharmacological agents are already 
widely used in humans,23 and the possibility of targeting 
NP-associated Ag directly to DCs as part of anticancer or 
antipathogen vaccine strategies have recently been explored 
in a variety of preclinical models.24,25
Here we describe a versatile PLGA-based NP that com-
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systems with specific DC targeting. In addition to quantifying 
antigen cross-presentation, we monitored the uptake efficiency 
and subcellular location of these Ag-encapsulated PLGA 
NPs within the DC. We report that DEC-205 targeting led to 
increased internalization of NPs by immature DCs, as well as 
endosomal release of the NP to the DC cytoplasm and enhanced 
levels of Ag cross-presentation of a clinically relevant mela-
noma epitope. To our knowledge, these data represent the 
first utilization of DEC-205 targeted NPs in Ag delivery 
experiments in human monocyte-derived DCs and indicated 
that these reagents show promise in potentially improving the 
potency of next-generation DC-based cancer vaccines.
Materials and methods
antibodies and reagents
antibodies
The antibodies used were anti-HLA-DR-FITC, mouse-IgG2b- 
FITC (both from BD Biosciences, San Jose, CA, USA); 
anti-CD83-PE, mouse-IgG1-PE (both from BioLegend, San 
Diego, CA, USA); anti-CD14-PerCP, mouse-IgG1k-PerCP, 
anti-CD11-APC, mouse-IgG1k-APC, biotinylated antihuman 
DEC-205 monoclonal antibody, biotinylated mouse IgG2bk 
(all from eBiosciences, San Diego, CA, USA); antihuman 
interferon (IFN)-γ enzyme-linked immunosorbent assay kit 
(BD Pharmingen, San Diego, CA, USA). 
cytokines
Recombinant human IL-4, tumor necrosis factor alpha 
(TNFα), IL-1β, and IL-6 were obtained from R&D Systems 
(Minneapolis, MN, USA). Prostaglandin E2 was obtained 
from MP Biomedicals (Irvine, CA, USA). Granulocyte-
macrophage colony-stimulating factor was obtained from 
Berlex (Seattle, WA, USA). 
synthetic biomolecules
Poly(vinyl alcohol), sodium deoxycholate, palmitic acid, 
N-hydroxysuccinimide ester, and gelatin were all purchased 
from Sigma-Aldrich (St Louis, MO, USA). Methylene 
chloride and avidin were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA) and Invitrogen (Carlsbad, 
CA, USA), respectively. Research-grade PLGA (50:50, 
approximately 50,000 g/mol), was purchased from Durect 
(Pelham, AL, USA).
Peptide and cell lines
Peptide
The HLA-A*0201-restricted peptide ELAGIGILTV (derived 
from the melanoma-associated differentiation antigen 
Melan-A/MART-1; A to L substitution at position 2 com-
pared with its natural counterpart for higher immunogenicity 
and referred to as MART-127–35), as well as the peptide labeled 
with a COOH-terminus FITC fluorochrome were produced 
by the Keck Facility (Yale University). 
cTl clone
The human CD8+ T-cell receptor transgenic cell line DMF5, 
reactive with both the MART-1(26–35) and MART-1(27L–35) 
epitopes, was kindly provided by John R Wunderlich, Sur-
gery Branch, National Cancer Institute. This line, originally 
derived from a high avidity tumor-infiltrating lymphocyte 
clone that mediated tumor regression clinically, has been 
extensively described previously.26
Media and serum
DC cultures were maintained in serum-free DC medium 
(Cell-Genix, Freiburg, Germany) supplemented with 1% 
normal autologous human serum. Human serum was isolated 
in our laboratory from healthy donors after informed con-
sent was obtained. Tumor-infiltrating lymphocyte cell lines 
were maintained in CTL medium: Roswell Park Memorial 
Institute 1640 medium supplemented with 12.5 mM, 4 mM 
L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin 
(Invitrogen), 50 μM β-mercaptoethanol (Sigma), and 10% 
normal human serum. The flow cytometry wash buffer was 
composed of phosphate-buffered saline (Invitrogen) supple-
mented with 2% fetal bovine serum (Gemini BioProducts, 
Woodland, CA, USA). 
synthesis of NPs and Dec-205 ligand 
coupling to the NP surface
PLGA NPs encapsulating MART-127–35 peptide (ELAGIG-
ILTV) (5 μg peptide/mg PLGA NP) were prepared and 
functionalized with avidin using a modified o/w emulsion 
and solvent evaporation–extraction method as described 
previously.27 Control NPs (blanks) were synthesized with 
sterile phosphate-buffered saline replacing the peptide. Fluo-
rescent NPs were formulated by incorporating a FITC-labeled 
MART-127–35 peptide by identical methodologies. Biotinylated 
anti-human DEC-205 monoclonal antibody or isotype control 
antibody was added at a concentration of 10 μg/mg PLGA 
NPs in phosphate-buffered saline and rotated for 40 minutes 
at room temperature; this antibody concentration was deter-
mined to lead to near 100% incorporation on the NP surface as 
previously described.19 The particles were then centrifuged at 
6,500 rpm for 5 minutes, washed twice in phosphate-buffered 
saline, and resuspended in DC medium prior to loading.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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Nanoparticle characterization 
Initial images of the NPs were taken by scanning electron 
microscopy. The NPs were analyzed using a NS500 instru-
ment (NanoSight, Amesbury, UK) and NTA 2.0 software to 
determine their concentration and size distribution. The lyo-
philized NPs were dispersed in phosphate-buffered saline at 
dilute concentrations (25 μg/mL) prior to analysis. The Nano-
Sight instrument captures the motion of individual particles 
in suspension using microscopy, and the software derives the 
concentration and hydrodynamic radii of individually tracked 
particles, producing a high-resolution size distribution with 
each measurement. The mean, mode, standard deviation, and 
coefficient of variation of each distribution were calculated 
by the software. 
The dispersity of the size distribution (Ð) was calculated 
by the following formula:
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where Mw is the weight-average molecular weight and Mw is 
the number-average molecular weight. Taking the assump-
tion that all NPs have equal density, we instead use the vol-
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where V is the volume of each NP in the distribution.
The MART-1 peptide content of the peptide-loaded NPs 
was determined by high-performance liquid chromatographic 
analysis of degraded NPs. Specifically, 1.5 mg of the MART-
1-NP complex was dissolved in 100 μL 8 M urea/0.4 M 
ammonium bicarbonate, followed by acidification in 20% tri-
fluoroacetic acid and addition of 100 μL of 100% acetonitrile. 
Samples were spun through a 0.2 Millipore microfilter to 
ensure removal of residual particulate matter and a 10 μL 
sample was run on an HP1090 high-performance liquid chro-
matography system with a Vydac C18 reverse phase (1 mm × 
250 mm eluted at 50 μL per minute) column. The peptide 
concentration was determined by monitoring of the peptide 
backbone at 210 nm on the instrument’s ultraviolet detector.
generation of fast Dcs from peripheral 
blood mononucleated cells of healthy 
human donors
Protocols for generating mature monocyte-derived DCs over 
a 48-hour period (instead of protocols 7–10 days long) have 
been described widely in the literature.28–31 Such shorter 
culture periods offer practical advantages of reduced time 
span and the amount of recombinant cytokines required. 
Briefly, after informed consent was obtained, peripheral 
blood mononucleated cells from healthy human donors (both 
HLA-A*0201+ and HLA-A* 0201−) were isolated by Ficoll-
Hypaque gradient centrifugation. Peripheral blood mononu-
cleated cells were resuspended in serum-free DC medium 
(Cell-Genix) supplemented with 1% normal human serum, 
and plated at 15×106 cells/3 mL/well of a 6-well tissue culture 
plate. After a 90-minute incubation at 37°C, non-adherent 
cells and medium were removed and replaced with 3 mL/
well of fresh DC medium. After a second incubation period 
at 37°C for 60 minutes, non-adherent cells and medium were 
again removed and replaced with 3 mL/well of DC medium 
supplemented with 800 IU/mL granulocyte-macrophage 
colony-stimulating factor and 1,000 IU/mL IL-4. After one 
day of incubation at 37°C with 5% CO2, a cytokine cocktail 
of 10 ng/mL TNFα, 10 ng/mL IL-1β, 1,000 IU/mL IL-6, and 
1 μg/mL prostaglandin E2 was added directly to the cultures. 
Cultures were incubated at 37°C for an additional day before 
mature DCs were harvested. 
Phenotype of FastDcs and expression  
of Dec-205 on FastDcs
The phenotype of “fast” DCs, including the expression of 
DEC-205, was determined by flow cytometry. For analysis 
of FastDCs, the following primary antibodies and their 
appropriate isotype controls were used: anti-CD83-PE, 
anti-CD14-PerCP, anti-CD11c-APC, and anti-DEC-205-PE. 
Cells were analyzed on a FACS Calibur flow cytometer 
(Becton Dickinson, Heidelberg, Germany). The data were 
analyzed using FlowJo version 7.6.2 software. The gates 
were based on isotype controls. 
MART-1-specific CD8+ T-cell responses
Human immature DCs were collected and incubated for 
5 hours at 37°C with varying concentrations of anti-DEC-
205 or isotype control-coated NPs containing MART-127–35 
peptide (250 μg NPs/mL medium, 125 μg/mL, 62.5 μg/mL, 
31.25 μg/mL). Maturation cocktail (TNFα, IL-6, prostaglan-
din E2, and IL-1β) was subsequently added. One day later, 
the mature DCs were harvested, tested by flow cytometry, 
and cocultured for 72 hours with the MART-1-specific CD8+ 
clone DMF5 (recognizing MART-127–35) at a 1:2 DC⁄ T-cell 
ratio. The efficiency of antigen presentation was evaluated 
in an IFN-γ enzyme-linked immunospot assay. Unstimulated 
CD8+ T-cells alone and T-cells stimulated using DCs loaded International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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with blank PLGA NPs (at identical NP concentrations to 
those containing MART-127–35 peptide) acted as negative 
controls. Experiments were performed in triplicate. IFN-γ 
release was fitted to a sigmoidal response curve as follows:
  YB
AB
EC H =+
−
+
− 11 0 50 log( ) X
where X is the logarithm of concentration, Y is the response, 
A and B are the initial and final responses, respectively, H 
is the Hill slope, and EC50 is the half-maximal stimulation 
value.
Measurement and visualization  
of NP uptake
NP uptake was assessed by flow cytometry as well as a 
variety of imaging modalities. Human immature DCs were 
collected and incubated for 5 hours at 37°C with varying 
concentrations of anti-DEC-205 or isotype control-coated 
NPs containing fluorescent dye (FITC)-labeled MART-127–35 
peptide (250 μg NPs/mL medium, 125 μg/mL, 62.5 μg/mL, 
31.25 μg/mL). Maturation cocktail (TNFα, IL-6, prosta-
glandin E2, and IL-1β) was subsequently added. After over-
night culture at 37°C, the cells were washed twice and then 
labeled with antihuman-CD11c-APC for 30 minutes at 4°C. 
After staining, the cells were washed and analyzed by flow 
cytometry. Differences in median fluorescence intensity for 
FITC (fluorescently labeled MART-1) were determined. DCs 
loaded with blank PLGA NPs acted as negative controls. To 
control for non-specific binding, a fraction of cells treated 
with fluorescent peptide NPs were incubated at 4°C. 
To visualize internalization of NPs and to determine 
colocalization with the endolysosomal compartment, 
transmission electron microscopy (TEM), confocal micro-
scopy, and Amnis ImageStream® were utilized. For TEM, 
nanospheres were cocultured with DC preparations for   
90 minutes at 37°C, and washed extensively. Cells were fixed 
in 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M 
cacodylate buffer, and post-fixed in 1% OsO4 for one hour 
at room temperature. After en bloc staining with 2% uranyl 
acetate, cells were dehydrated and embedded in Epon. Thin 
sections (50 nm) were cut with an ultramicrotome and metal 
stained with uranyl acetate and lead citrate, before viewing 
in a Tencai™ Bio-twin transmission electron microscope 
(FEI Company, Hillsboro, OR, USA) at 80 kV. Images were 
acquired by a Morada charge-coupled device camera fitted 
with iTEM software (Olympus, Tokyo, Japan). Confocal 
microscopy was carried out on DC preparations following a 
3-hour internalization period and the cells were visualized on 
Alcian blue-coated coverslips utilizing an LSM510 META 
instrument (Carl Zeiss, Oberkochen, Switzerland) with a 63× 
objective lens, and image analysis and three-dimensional 
reconstructions performed with Volocity 6.0 software 
(Perkin-Elmer, Waltham, MA, USA). ImageStream® colocal-
ization was determined from identical DC preparations, with 
image analysis performed utilizing an Amnis ImageStream 
instrument with the IDEAS software package and the “Simi-
larity Score” algorithm.
Results
Nanoparticle preparation and 
characterization
As previously described,27,28 we utilized a strategy for surface 
modification of PLGA particles by introducing functionally 
active avidin coupled to palmitic acid during the emulsion 
preparation of the particles. The addition of avidin-palmitic 
acid results in incorporation of avidin at high density on the 
surface of the NP. The surface of these particles may then 
be further modified by addition of biotinylated proteins 
that bind avidin with high affinity. This system allows for 
prolonged presentation of these proteins over the course of 
several weeks while release of encapsulated proteins from 
the PLGA matrix is unhindered.27 
In the experiments reported here, we have used these PLGA 
NPs, which contain encapsulated MART-127–35 peptide as an 
Ag source, with either biotinylated isotype control monoclonal 
antibody (immunoglobulin G2b) or biotinylated anti-DEC-
205 monoclonal antibody-targeting antibody decorating the 
surface (Figure 1A). Scanning electron microscopic images 
revealed that the NPs were spherical in shape, with a smooth 
surface and a size distribution in the 200 nm range (Figure 1B).   
NanoSight analysis confirmed this size distribution, with 
very similar values obtained for particles with or without 
attached monoclonal antibody; PLGA particles alone had a 
modal diameter of 193 nm, while DEC-205-coated particles 
had a modal diameter of 196 nm (Figure 1C). Variations in 
size distribution and dispersity due to DEC-205 binding were 
minimal (Figure 1D). The MART-127–35 peptide content of NP 
preparations was determined to be 1.1 μg peptide/mg polymer, 
representing an encapsulation efficiency of 22%. This concen-
tration was quantified from peptide released from degraded 
NP preparations, with analysis performed on a C18 reverse 
phase high-performance liquid chromatography system and 
ultraviolet absorbance determined by monitoring the peptide 
backbone at 210 nm, since no chromophoric residues such as 
tryptophan or tyrosine were present in the sequence.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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FastDc protocol generates mature 
monocyte-derived Dcs
In the recently developed FastDC protocol,29,30 monocytes 
are incubated with granulocyte-macrophage colony-stim-
ulating factor and IL-4 for 24 hours and are subsequently 
activated with a combination of proinflammatory media-
tors (TNFα, IL-1β, IL-6, and prostaglandin E2) for another 
24 hours to rapidly generate mature and fully functional 
DCs. This differentiation protocol has been confirmed to 
generate immunostimulatory DCs with equal potency of 
those derived from 7–10-day cultures.31,32 To confirm this 
in our system, cells were monitored for DC differentiation 
by staining for the monocyte marker CD14 and maturation 
marker CD83 during the differentiation and maturation 
period. Before administration of the maturation cocktail, 
the cells displayed an immature DC phenotype (CD83low 
CD14high; Figure 2, left panel), whereas just 24 hours after 
adding the maturation cocktail, the majority of the cells 
had differentiated into fully mature DCs (CD83high CD14low; 
Figure 2, right panel). Phenotypic characterization of three 
additional donor DC cultures of differing HLA subtypes 
confirmed the FastDC protocol uniformly generated mature 
DC phenotypes (Figure S1).
Dec-205 is expressed on both immature 
and mature human monocyte-derived 
Dcs
DEC-205 is highly expressed on a variety of murine and 
human DC populations and is therefore an excellent candi-
date for specific targeting of Ag through receptor-mediated 
endocytosis of DEC-205 antibody-coated NPs. To assess 
the potential efficacy of using DEC-205 targeting with 
monocyte-derived DCs for vaccination, we followed the 
expression of DEC-205 during the development and matura-
tion of human monocyte-derived DCs (Figure 2, left and right 
panel bottom). DEC-205 expression increased consistently 
during FastDC development, as indicated by the increas-
ing specific median fluorescence intensity. The majority of 
immature DCs were DEC-205-positive (Figure 2, left panel, 
day 1); however, the expression level further increased during 
Figure 1 DEC-205 surface-modified nanoparticles encapsulating MART-1 peptide.
Notes: (A) Schematic representation of PLGA nanoparticles. Nanoparticles surface-modified with avidin to facilitate binding of a biotinylated ligand, either anti-DEC-205 
monoclonal antibody or isotype control (immunoglobulin g2b) monoclonal antibody. (B) Scanning electron microscopy image of surface-modified PLGA nanoparticles with 
an average diameter of 200±6.5 nm. (C) size distribution of nanoparticles in suspension as measured by Nanosight. (D) Tabulated characteristics of the size distributions 
obtained by Nanosight, averaged across three measurements.
Abbreviations: Plga, poly(lactic-co-glycolic acid); sD, standard deviation; se, standard error.
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maturation (Figure 2, right panel, day 2). Having established 
that the majority of both immature DCs and mature DCs were 
DEC-205-positive in the human system, we next sought to 
investigate whether these FastDC populations could serve 
as targets for NP-mediated tumor Ag delivery.
Tumor ag delivered via Dec-205 to 
human monocyte-derived Dcs are more 
efficiently cross-presented to CD8+ T-cells
Cross-presentation of endocytosed tumor-associated antigens 
to cytotoxic CD8+ T-cells is essential for the induction of 
antitumor immunity.17,33 To investigate whether antigens 
delivered to monocyte-derived DCs via DEC-205 are more 
efficiently cross-presented to CD8+ T-cells, we used anti-
DEC-205-coated PLGA NPs with encapsulated MART-127–35 
peptide, and compared them with MART-127–35 peptide-
loaded NPs coated with isotype control antibody. 
As shown in the flow chart represented in Figure 3A, we 
first prepared fast monocyte-derived DCs from an HLA-A2-
positive donor, and these DCs were subsequently exposed 
for 24 hours to either DEC-205-targeted MART-127–35 NPs, 
control immunoglobulin G-coated MART-127–35 NPs, or 
blank NPs with no encapsulated Ag. To determine the 
effects of targeting NPs to DEC-205 on DCs, the different 
groups of NP-loaded DCs were cocultured with an HLA-A2 
restricted CD8+ CTL line recognizing MART-127–35 (DMF5) 
for 72 hours at a DC to T-cell ratio of 1:2. IFN-γ production 
from the supernatants was compared as a measure of cross-
presentation of MART-127–35 peptide to CD8+ T-cells. 
DCs exposed to either preparation of MART-127–35-
containing NPs produced significant quantities of IFN-γ 
(Figure 3B). However, we observed that compared with 
isotype-coated NPs, DCs exposed to DEC-205 targeted NP 
had a greater than 1.5-fold increase in IFN-γ production by 
Figure 2 expression of markers of maturation and Dec-205 on FastDcs.
Notes: FastDcs were generated by culture of adherent monocytes in GM-CSF and IL-4 over the course of 2 days. Maturation was induced over the final 24 hours of 
culture with addition of TNFα, Il-6, Pge2, and Il-1β. Cells were harvested at days 1 and 2, and analyzed for CD83, CD14, and DEC-205 using flow cytometry. The data are 
representative of three independent experiments performed with Dcs from different donors. red histograms represent isotype controls, and blue histograms represent 
cells stained with specific antibodies.
Abbreviations: gM-csF, granulocyte-macrophage colony-stimulating factor; Il, interleukin; TNFα, tumor necrosis factor alpha; Pge2, prostaglandin e2; Dc, dendritic cell; 
PBMc, peripheral blood mononucleated cells.
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MART-1-specific CD8+ T-cells. These results indicate that 
DEC-205-mediated delivery to DCS led to more efficient 
CD8+ T-cell stimulation, a result that was observed at all NP 
concentrations tested. DCs stimulated with blank NPs (con-
taining no Ag) and coated with either DEC-205 or isotype 
control produced negligible levels of IFN-γ compared with 
MART-127–35-containing NPs under these conditions (Figure 
3B, triangles), indicating minimal levels of non-specific 
stimulation. In addition, DCs loaded with irrelevant soluble 
peptide (gp-100) or the soluble MART-127–35 peptide were 
PBMC of healthy HLA A2+ donors
GM-CSF/IL-4 24 hours
Immature DC
NPs added (DEC-205 targeted or non-
targeted) and containing MART-127–35
peptide or PBS (“blank”), followed by 
O/N maturation stimulus
24 hours
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(Co-cultured with DMF5 CD8+ T-cell line (MART-127–35-specific) at a DC:T-cell ratio of 1:2)
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Figure 3 enhanced antigen cross-presentation by Dcs loaded with anti-Dec-205-coated nanoparticles.
Notes: (A) Overview of Dc-based cross-presentation assays. Immature Dcs were generated by the FastDc protocol and incubated with targeted or control NPs either 
without antigen (blank, NP-IsO or NP-Dec) or containing MarT-1 peptide (NP-MarT-IsO or NP-MarT-Dec) for a total of 24 hours. Maturation stimuli (TNFα, Il-6, 
Pge2, and Il-1β) were given to Dcs after an initial 5 hours of NP pulse. Mature Dcs were harvested, washed, and cocultured for 72 hours with MarT-127–35-specific DMF5 
cD8+ T-cells. supernatants were then harvested and analyzed with an IFN-γ  elIsa assay. (B) NPs were added at varying concentrations (250 μg/ml, 125 μg/ml, 62.5 μg/ml,   
31.25 μg/mL) to DCs and then cocultured with antigen-specific T-cells. Total IFN-γ production was proportional to the efficiency of DC antigen cross-presentation. At all 
concentrations tested, Dec-205-mediated antigen delivery (circles) led to superior T-cell stimulation compared with isotype control NPs (squares) or no antigen NPs (triangles). 
The graph shows the mean (± standard deviation) for IFN-γ production in triplicate and is a representative example of three experiments with different hla-a2 donors.
Abbreviations: gM-csF, granulocyte-macrophage colony-stimulating factor; Il, interleukin; Pge2, prostaglandin e2; PBMc, peripheral blood mononucleated cell; PBs, 
phosphate-buffered saline; IFN-γ, interferon gamma; elIsa, enzyme-linked immunosorbent assay; hla, human leukocyte antigen; Dc, dendritic cell; NP, nanoparticle; IsO, 
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included as additional negative and positive controls, respec-
tively (data not shown). These results indicated that specific 
targeting of Ag through the DEC-205 receptor, rather than 
non-specific binding and internalization of antibody-coated 
NPs through DC Fc receptors, was responsible for the 
increase in DC Ag cross-presentation observed.
To confirm that no significant toxicity was associated 
with antibody-coated PLGA NPs, immature DCs treated 
identically to those described above (with highest NP 
concentration) were incubated with maturation cocktail 
or maturation cocktail along with either isotype control-
coated or anti-DEC-205-coated NPs for 24 hours. Using a 
propidium iodide staining solution, the CD11c+ cell death 
percentage was measured with flow cytometry after overnight 
incubation. The results showed that NPs were not toxic to 
DCs and more than 90% of cells were still viable following 
this extended incubation, only slightly more than DCs that 
received no NPs (Figure S2).
Targeting NPs to Dec-205 on Dcs  
leads to enhanced NP uptake 
To determine whether differential IFN-γ production by 
MART-1-specific CD8+ T-cells was associated with more 
efficient NP uptake mediated by DEC-205, we measured par-
ticle internalization as a function of NP concentration. Flow 
cytometry-based monitoring of NP uptake was facilitated by 
fabrication of fluorescently labeled MART-127–35 NPs, and 
these fluorescent nanospheres were then surface-modified with 
either anti-DEC-205 antibody or isotype control monoclonal 
antibody. Immature fast DCs were exposed to varying concen-
trations (250 μg/mL, 125 μg/mL, 62.5 μg/mL, 31.25 μg/mL,   
or 15.62 μg/mL) of isotype control-coated NPs or anti-DEC-
205-coated NPs for 5 hours at 4°C and 37°C and then matured 
overnight in maturation cocktail. Analysis of particle uptake 
was carried out by flow cytometry, with total fluorescence 
proportional to the total number of NPs internalized by DCs. 
Numbers represent median fluorescence intensity following 
subtraction of the control 4°C signal (non-specific surface 
binding) from 37°C values (internalized NPs). As shown in 
Figure 4, although isotype-coated NPs were taken up by DCs 
to some degree (dashed squares), significantly increased fluo-
rescence intensity was associated with anti-DEC-205-coated 
NPs (solid line circles) indicated that the specific internaliza-
tion mediated through the DEC-205 receptor was driving 
higher levels of receptor-mediated endocytosis. And although 
the difference in uptake could be observed at low NP concen-
trations, it was much more pronounced at higher concentra-
tions (100 μg/mL), indicating that antibody-coated NPs 
in general were internalized by Fc-mediated mechanisms; 
however, specifically targeted DEC-205 NPs were associated 
with additional endocytic or phagocytic activity that did not 
plateau even at high particle concentrations. These results 
also indicate that the previously observed increases in Ag 
cross-presentation efficiency (Figure 3B) associated with 
DEC-205-mediated delivery could be explained largely by 
increased levels of NP internalization. DCs loaded with blank 
NPs containing no fluorescent Ag were used as controls (rep-
resented by dashed triangles directly on x-axis in Figure 4). 
No significant uptake was detected when DCs were exposed 
to particles and kept at 4°C (data not shown). 
Intracellular localization of targeted NP
To determine whether targeted NPs deliver increased Ag to 
the traditional endolysosomal pathway or whether this Ag 
has increased access to the cytoplasmic MHC class I loading 
machinery, internalization and subcellular localization of 
DEC-205-targeted NPs was also assessed using TEM, confo-
cal microscopy, and ImageStream analysis (Figure 5A–C), 
to access NP delivery and residence in the endolysosomal 
compartment. Previous work by our group and others15 
(reviewed by Dahnier et al23) indicated that PLGA NPs 
escape the endosomal compartment and degrade in the 
cytoplasm of the DC, providing prolonged and enhanced 
Figure 4 Dec-205 receptor targeting leads to increased uptake of NPs by Dcs.
Notes: To determine the dose-dependence of the Dec-205-mediated increase in 
NP uptake, Dcs were exposed to MarT-1FITc peptide-fluorescent NPs at varying 
concentrations (250 μg/ml, 125 μg/ml, 62.5 μg/ml, 31.25 μg/ml, or 15.62 μg/ml) 
for 24 hours at 4°c and 37°c, followed by overnight incubation. The cells were 
harvested and stained with cD11c− antigen-presenting cells and flow cytometry was 
used to quantify FITc intensity for the gated cD11c+ cells. example of nanoparticle 
uptake by control Dcs (Dcs treated with blank NPs containing no FITc-labeled 
antigen; controls, triangles), Dcs incubated with isotype antibody-coated particles 
(NP-IsO, squares), or Dcs incubated with Dec-205-coated particles (NP-Dec, 
circles) are shown. Numbers represent MFI following subtraction of parallel control 
4°c signal.
Abbreviations: DC, dendritic cell; NP, nanoparticle; MFI, median fluorescence 
intensity; ISO, isotype control; FITC, fluorescein isothiocyanate.
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Figure 5 Confirmation of endosomal escape of DEC-205 NP following DC internalization.
Notes: (A) Transmission electron microscopic image of FastDc 90 minutes post Dec-205 NP or control latex bead loading. Plga NPs (Ai, arrows) are internalized by 
Dcs but are not surrounded by a classical endolysosomal double membrane, indicating that these NPs are able to escape the endosomal compartment and biodegrade in 
the cytoplasm. By contrast, 200 nM latex beads (Aii, arrows) are surrounded by an endolysosomal membrane from the time of formation of the endocytic cup at the cell 
surface (inset) to cup closing and complete engulfment. (B) Confocal microscopy showing flattened three-dimensional reconstructions of DCs that had internalized DEC-
205 NP. The lysosomal compartment was identified using the lysosome-associated marker LAMP-1 (blue) and the NPs localized utilizing a FITC-labeled MART-1 peptide 
as encapsulant (green). A large quantity of both single NPs and NP aggregates are not localized to LAMP-1-containing vesicles, confirming lysosomal escape of internalized 
particles. (Ci–Ciii) °represents secondary, or secondary antibody. amnis Imagestream colocalization analysis. Utilizing the Imagestream colocalization software, Dcs that 
had internalized the FITc-labeled Dec-205 NPs (green) were evaluated for the presence of colocalization with eea-1 or laMP-1+ compartments. as a positive control, a 
secondary antibody recognizing the Dec-205 antibody on the surface of the NP 2° (a680 [red]) showed extensive colocalization by both image and histogram (values 1 
indicating colocalization). In contrast, very little colocalization is observed between with the FITc NPs and eea-1+ endosome or laMP-1+ lysosome (Di and Dii), with image 
analysis showing clearly spatially separated signals and colocalization software histograms indicating little signal overlap.
Abbreviations: DC, dendritic cell; NP, nanoparticle; FITC, fluorescein isothiocyanate.
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Ag cross-presentation. Here we provide evidence from 
three different imaging modalities that targeted PLGA NPs, 
surface-labeled with a DEC-205 targeting antibody, also 
appear to “escape” lysosomal degradation and reside in the 
DC cytoplasm. TEM images of DCs that had internalized 
DEC-205-labeled PLGA NPs (Figure 5A, left panel, arrows 
and inset) confirm that the NPs are not surrounded by a 
classical endolysosomal double membrane, indicating that, 
following receptor-mediated endocytosis, a full membrane 
either does not form or is quickly destabilized by the NP, International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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leading to endosomal rupture and release to the cytoplasm. 
By comparison, when a non-PLGA NP of identical size, in 
this case a non-biodegradable, unlabeled latex bead (5A, 
right panel, arrows and inset), is internalized by identical 
DCs, a clear double membrane surrounds each particle. This 
indicates that DEC-205-coated PLGA NPs are preferentially 
excluded from the endolysosomal compartment, and instead 
reside (and presumably degrade) within the DC cytoplasm. 
This observation was confirmed by confocal micro-
scopy (Figure 5B), as three-dimensional reconstructions 
of DC that had internalized fluorescently labeled DEC-205 
NP (green), show extremely limited colocalization with a 
marker of the lysosomal compartment, LAMP-1 (blue). 
Single NPs or areas of accumulated multiple NPs are 
spatially separated from DC lysosomes, with little or no 
colocalized signal. These data indicate that the DEC-205 
NPs are not shuttled through the standard endolysosomal 
pathway, an observation that differs from larger particulate 
Ag which are targeted to the lysosomes for degradation and 
Ag presentation.34 Finally, ImageStream analysis confirmed 
the results obtained by TEM and confocal microscopy, indi-
cating low levels of intracellular colocalization with markers 
of the endolysosome (Figure 5C and D). The ImageStream 
system is designed to image cells under flow conditions and 
combines the capabilities of microscopy and flow cytometry 
in a single platform, allowing visualization of individual 
cells and simultaneous spatial localizations of intracellular 
signals. Each cell is represented by a bright field image and 
up to five fluorescent images (Figure 5C), and utilizing the 
instrument’s IDEAS software and “similarity” algorithm it 
is possible to quantitate colocalization of signals from dif-
ferent spectral channels and provide similarity histograms 
(Figure 5D). Thus, detection of fluorescent signal from an 
internalized FITC NP (Figure 5Cii) which is in the same 
spatial register as signal from the endolysosomal markers 
EEA-1 and LAMP-1 (Figure 5Cii) would be visualized as 
completely overlapping signal in overlays (Figure 5Cii). 
As a positive control for signal overlap, a labeled second-
ary antibody recognizing the DEC-205 antibody on the 
NP surface (Figure 5Ci), was included as an indicator of 
complete colocalization. As shown in the upper fluorescent 
panel (Figure 5Ci) and associated histogram (Figure 5Ciii), 
this control exhibited near 100% colocalization (where 
histogram values 1 indicate increasing degrees of over-
lap). This is in sharp contrast to the localization associ-
ated with the endolysosomal panel (Figures 5Ci and 5D), 
where a comparatively limited degree of colocalization is 
observed.
Taken together, these data indicate that increased Ag 
presentation associated with DEC-205-mediated Ag deliv-
ery could result from a combination of more efficient NP 
internalization (Figure 4) as well as differential delivery of 
NP conjugates to the DC cytoplasm (Figure 5). 
Discussion 
Activating the immune system to trigger a sufficient cytotoxic 
T lymphocyte-mediated response is a major challenge in the 
development of successful therapeutic vaccines against patho-
gens and cancer. Currently, there are no human peptide-based 
cancer vaccines on the market, mostly because of the diffi-
culties associated with their poor immunogenicity, stability, 
and delivery. Our group15,17,35–38 and others39–42 have described 
strategies to enhance peptide/protein immunogenicity and 
stability by directing Ag to DCs using particulate delivery sys-
tems. The particulate nature of these delivery vehicles permits 
their rapid internalization by DCs and their composition can 
provide adjuvant properties required for immunogenicity.18 
Ag encapsulated in NPs and targeted to APC are protected 
from enzymatic degradation, and processed and presented to 
T lymphocytes after their delivery to the APC. 
Receptors previously used for DC targeting, such as DEC-
205 as a protein Ag conjugate, have the ability to deliver 
antigens to late endosomal elements that serve as efficient sites 
for the formation of immunogenic peptides and their loading 
onto MHC class II molecules (which are needed for CD4 T-cell 
and antibody responses).43,44 Effective vaccination, however, 
will also often require the production of CD8 cytotoxic T-cell 
responses that occur only when antigen is present in the cyto-
plasm. DCs are adept at this function via the process of “cross-
presentation”, whereby exogenous antigens escape endocytic 
vesicles and enter the cytoplasm where they are cleaved into 
peptides by the proteasome, imported into the endoplasmic 
reticulum, and loaded onto newly synthesized MHC class I 
molecules (which are required for stimulation of CD8 T-cells). 
In previous work, we have found that it is possible to greatly 
enhance the efficiency of cross-presentation by artificially caus-
ing the limited disruption of endosome-lysosome membranes 
during antigen uptake.15 Our results indicate that this can be 
accomplished in vitro with DEC-205-targeted PLGA NPs. 
This approach is directly analogous to that taken by many 
pathogens, including viruses, such as adenovirus, reovirus, 
and papillomavirus, that effect endosome disruption in order 
to gain access to the cytosol for purposes of infection.45–48 
Here we have shown that surface modification of Ag-
loaded NPs to direct them to DCs affects the outcome of 
the immune response towards the delivered antigen. Several International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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studies have demonstrated that targeting soluble Ag to DCs 
via DEC-205 fusion proteins leads to improved receptor-
mediated endocytosis and Ag presentation.4,8,19 Furthermore, 
the concept of targeting DEC-205 via particulate delivery to 
DCs has been introduced in mice, with Kwon et al using pH-
responsive microparticles surface-conjugated with the anti-
DEC-205 monoclonal antibody to demonstrate that targeting 
DEC-205 enhances particle uptake and Ag presentation,49 as 
well as our groups’ demonstration that the density of DEC-
205 on the NP surface is crucial to controlling murine DC 
antigenicity.19 However, these findings have not yet been 
extended to relevant human in vitro experiments that mimic 
current DC vaccinations utilizing monocyte-derived DCs, 
although data exist suggesting possible utility in DEC-205 
targeting of plasmacytoid DCs.9 For the first time, we dem-
onstrate here that targeting human monocyte-derived DCs in 
vitro via DEC-205 using biodegradable PLGA NPs leads to 
enhanced stimulation of relevant antitumor CD8+ T-cells. 
To target DCs in vitro and to initiate a directed CTL-me-
diated immune response, PLGA NPs coated with anti-DEC-
205 monoclonal antibodies were used as a delivery system 
to load clinically relevant, melanoma-associated antigen-
derived peptide, MART-127–35, into human DCs (Figure 1A). 
A beneficial feature of the use of anti-DEC-205 monoclonal 
antibody-conjugated particles is that mature DCs as well as 
immature DCs are targeted. Birkholz et al reported that mature 
DCs express high levels of DEC-205 on their cell surface 
and are able to stimulate naïve T-cells with high efficiency.8 
As DEC-205-expression was observed on both immature 
and mature monocyte-derived DCs in our experiments 
(Figure 2A), in vitro DEC-205 targeting of DCs was carefully 
analyzed, and its impact on DC phenotype and functionality 
was investigated. Four different DC populations were stud-
ied (Figure 3A): DCs loaded with MART-127–35 containing 
anti-DEC-205-coated NPs; DCs loaded with MART-127–35   
containing isotype-coated NPs; and DCs loaded with blank 
NPs similarly labeled. We observed that the MART-127–35 
peptide delivered via anti-DEC-205-coated NPs was more 
efficiently cross-presented to MART-127–35-specific CD8+ 
T-cells (Figure 3B), and also determined that increased levels 
of Ag presentation were paralleled by increased levels of NP 
internalization (Figure 4). Importantly, in this study, we used 
patient-derived CD8+ CTL lines and peptides previously uti-
lized in a large group of clinical trials, ensuring the translation 
relevance of these reagents. 
Having demonstrated the increased Ag cross-presentation 
capability of anti-DEC-205-coated NPs, we wished to inves-
tigate the underlying mechanism driving these findings. We 
suggest two possibilities for this enhancement of Ag pre-
sentation: increased uptake of the anti-DEC-205-coated NPs 
by DCs and/or that uptake via DEC-205 results in transport 
of NPs to intracellular compartments involved in antigen 
processing for MHC I cross-presentation. 
DCs are known to uptake soluble and particulate Ag by 
means of macropinocytosis, so can internalize relatively small 
particles compared with macrophages. Therefore, to further 
enhance DC-specific uptake, it is important to target these 
cells by using NP surface moieties which stimulate through 
DC endocytic receptors. As DEC-205 is a well-defined DC-
associated lectin receptor, previously shown to facilitate Ag 
delivery and increased MHC I and II DC presentation,4,8 NPs 
conjugated with anti-DEC-205 monoclonal antibody are a 
logical next step in improving DC vaccine potency. We show 
here that human DCs more efficiently internalize DEC-205-
labeled NPs than particles conjugated to isotype monoclonal 
antibody, indicating that DEC-205 NPs can signal through 
both DC Fc receptors and DC lectin receptors (Figure 4). 
These results clearly indicate that enhanced DC-specific 
endocytosis of particles achieved through their conjugation 
with anti-DEC-205 antibody is one of the likely drivers of 
the enhanced Ag presentation observed. 
Besides simple increases in Ag internalization, 
another potential mechanism explaining the increased 
cross-presentation associated with DEC-205 NP-mediated 
Ag delivery is the potential access of these NP conjugates to 
the cytoplasmic MHC class I machinery. This access would 
circumvent the need for “traditional” cross-presentation 
through the vacuolar or phagosome-to-cytosol pathways 
currently proposed to explain DC cross-presentation,50,51 
which was a possibility proposed previously by our group 
following biochemical and microscopic analysis of DCs 
loaded with unmodified NPs.15 Here we provide additional 
confirmatory evidence that the phenomenon of “endosomal 
escape” of PLGA NPs can also be extended to NPs surface-
modified with DEC-205. Escape of NPs from the endolyso-
somal compartment has become an increasingly accepted 
mechanism for PLGA NP utility in drug and Ag delivery,23 
although some conflicting reports exist,34 most likely because 
of the use of microparticles versus NPs in DC loading and 
the inherent differences in the way in which large particles 
are routed intracellularly. Utilizing evidence from three dif-
ferent imaging modalities, ie, TEM, confocal microscopy, 
and ImageStream analysis, we show that DEC-205-targeted 
NPs appear to “escape” lysosomal degradation by avoiding 
routing to the endolysosomal pathway, and instead reside in 
the cytoplasm following internalization. TEM images of DCs International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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that had internalized DEC-205-labeled NPs (Figure 5A, left 
panel) confirm that the NPs are not surrounded by a classical 
endolysosomal double membrane, indicating that a traditional 
membrane either does not form properly or is quickly ruptured 
by the NPs, leading to NP release to the cytoplasm. In contrast, 
when a non-biodegradable particle, in this case latex beads 
of identical size (Figure 5A, right panel), is internalized by 
a DC, a phagosomal membrane is clearly present from the 
formation of the phagocytic cup to complete engulfment of the 
internalized particle. This cytosolic localization of DEC-205- 
labeled PLGA NPs was confirmed by confocal microscopy 
(Figure 5B), as internalized FITC-labeled NPs show limited 
colocalization with the lysosomal marker LAMP-1, with clear 
spatial separation between the DC lysosomes and single or 
aggregated NPs. Finally, ImageStream analysis confirmed 
these results, indicating low levels of intracellular colocaliza-
tion with markers of the endolysosome (Figure 5C and D).   
Taken together, these data indicate that DEC-205 NPs 
degrade within DCs in fundamentally different subcellular 
compartments than other particulate Ag, which are generally 
targeted to the lysosomes for degradation and traditional 
MHC class I and II presentation. Further studies are underway 
to determine whether DEC-205-labeled NPs are shunted to 
intracellular compartments in a mechanistically similar or 
different way when compared with control antibody-labeled 
NPs or untargeted particles; this will help define whether the 
increase in T-cell stimulation associated with targeted NPs is 
the result of simple increases in incorporation of DEC-205-
labeled NPs into DCs or the differential transport of DEC-205 
Ag once internalized by the cell, a phenomenon previously 
described for this ligand.52
In summary, the development of DC-targeting NP 
vaccine reagents derived from clinically relevant tumor 
antigens holds great promise. The results presented here 
indicate that DEC-205 receptor-mediated targeting of 
tumor Ag to DCs is a safe and effective methodology to 
heighten antigen uptake and subsequent CD8+ T-cell stimu-
lation by DCs, which are features essential to improving 
DC vaccine potency. Recent advances in NP technology 
allow for many variations in the design of NPs, including 
simultaneous delivery of antigens, immunomodulators, or 
other compounds and targeting moieties, creating a potent 
multivalent therapeutic strategy. The reagents described 
here, which remain focused on utilizing only reagents 
approved by the US Food and Drug Administration and 
real-world fabrication techniques, are another example of 
these advances that potentially represent a significant step 
forward in vaccine development.
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Figure S1 Confirmation of the FastDC phenotype from multiple donors.
Notes: To ensure the 48-hour FastDc protocol generates uniformly mature Dcs useful as antigen-presenting cells in T-cell stimulation assays, three separate human Dc 
cultures were phenotypically characterized following addition of gM-csF/Il-4 alone or cytokine plus maturation stimuli. Paired Dc cultures were analyzed for coexpression 
of costimulator molecules cD80 and cD86 (left) or Mhc class II and cD83 (right), hallmarks of a mature Dc phenotype. For all three donor cultures tested, a classically 
mature phenotype characterized by co-expression of high levels of costimulators cD80 and cD86, as well as increasingly positive hla-Dr (Mhc class II) combined with 
expression of maturation marker CD83, is associated uniformly with all DCs generated by the rapid FastDC protocol. These data confirm that mature, immunostimulatory 
Dcs were utilized in subsequent T-cell presentation assays.
Abbreviations: gM-csF, granulocyte-macrophage colony-stimulating factor; Il, interleukin; hla, human leukocyte antigen; Mhc, major histocompatibility complex;   
Dc, dendritic cell.
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Figure S2 Dec-205 NPs are not toxic to monocte-derived dendritic cells.
Notes: Dendritic cells treated with the highest NP concentration utilized (250 μg/ml) and were incubated with maturation cocktail or maturation cocktail along with either 
unlabeled, ISO-coated, or anti-DEC-205-coated NPs for 24 hours. Utilizing a propidium iodide staining solution and flow cytometry, the cell death percentage in CD11c+ 
was measured and compared between treatment groups. Minimal toxicity was observed in all treatment groups, with each exhibiting greater than 90% cells viable following 
incubation. graph shows the mean (± standard deviation) for propidium iodide-positive cells from three different hla-a2 donors.
Abbreviations: Dc, dendritic cell; NP, nanoparticle; IsO, isotype control.